Hepion Pharmaceuticals (NASDAQ:HEPA) jumped ~11% in premarket in reaction to positive data from a study of CRV431 conducted by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH).
CRV431 demonstrated positive antiviral activity against SARS-CoV-2, and showed to inhibit production of infectious virus with almost five-times greater potency than the positive control compound in the study. The concentration of CRV431 required to inhibit virus production by 90% was 1.5 µM versus 7.3 µM for the positive control compound. Also the drug candidate did not show significant cellular toxicity.
In preclinical studies, the drug showed encouraging action in COVID-19 models.
CRV431 Phase 2 study in NASH is ongoing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.